9.76

1.35% 0.13

After Hours: 9.76

Stoke Therapeutics Inc (STOK)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Stoke Therapeutics Inc stock is traded at $9.76, with a volume of 719.45K. It is up +1.35% in the last 24 hours and up +29.10% over the past month. Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Previous Close:

$9.63

Open:

$9.72

24h Volume:

719.45K

Relative Volume:

0.88

Market Cap:

$532.90M

Revenue:

$8.78M

Net Income/Loss:

$-104.70M

P/E Ratio:

-4.1181

EPS:

-2.37

Net Cash Flow:

$-82.68M

1W Performance:

+4.27%

1M Performance:

+29.10%

6M Performance:

-18.87%

1Y Performance:

-30.43%

1-Day Range:

$9.56

$10.06

1-Week Range:

$8.7032

$10.44

52-Week Range:

$5.35

$17.58

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name

Stoke Therapeutics Inc

Sector

Healthcare (1170)

Industry

Biotechnology (671)

Phone

781-430-8200

Address

45 WIGGINS AVENUE, BEDFORD, MA

Employee

128

Twitter

@stoketx

Next Earnings Date

2025-03-18

Latest SEC Filings

STOK's Discussions on Twitter

Compare STOK with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
STOK Stoke Therapeutics Inc	9.76	511.03M	8.78M	-104.70M	-82.68M	-2.37
ONC Beigene Ltd Adr	228.38	25.07B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	438.65	109.14B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.27	36.39M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	594.32	56.98B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	71.31	5.39B	0	-153.72M	-103.81M	-2.00

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-24	Initiated	Chardan Capital Markets	Buy
Oct-14-24	Resumed	Leerink Partners	Outperform
Mar-26-24	Upgrade	TD Cowen	Market Perform → Outperform
Nov-20-23	Resumed	JP Morgan	Neutral
Jul-25-23	Downgrade	TD Cowen	Outperform → Market Perform
May-01-23	Upgrade	BofA Securities	Underperform → Neutral
Apr-26-23	Resumed	Canaccord Genuity	Buy
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform
Oct-24-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-31-22	Initiated	Jefferies	Buy
Dec-03-21	Initiated	BofA Securities	Buy
Nov-22-21	Upgrade	JP Morgan	Neutral → Overweight
May-18-21	Initiated	UBS	Neutral
May-10-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Feb-10-21	Downgrade	Wedbush	Outperform → Neutral
Dec-15-20	Resumed	H.C. Wainwright	Buy
Dec-11-20	Reiterated	Needham	Buy
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight
Sep-29-20	Resumed	JP Morgan	Neutral
Sep-29-20	Initiated	Needham	Buy
Dec-18-19	Initiated	Wedbush	Outperform
Nov-12-19	Initiated	BTIG Research	Buy
Oct-25-19	Initiated	H.C. Wainwright	Buy
Jul-15-19	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Cowen	Outperform
Jul-15-19	Initiated	Credit Suisse	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight

View All

Stoke Therapeutics Inc Stock (STOK) Latest News

01:33 AM

HC Wainwright Analysts Decrease Earnings Estimates for STOK - Defense World

01:33 AM

Q2 EPS Estimates for Stoke Therapeutics Raised by Wedbush - Defense World

01:33 AM

May 16, 2025

Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet - sharewise

May 16, 2025

HC Wainwright Lowers Stoke Therapeutics (NASDAQ:STOK) Price Target to $35.00 - Defense World

May 16, 2025

May 15, 2025

Stoke Therapeutics stock target cut to $35 by H.C. Wainwright - Investing.com Canada

May 15, 2025

Price T Rowe Associates Inc. MD Purchases 2,215 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

May 15, 2025

May 14, 2025

STOK: HC Wainwright & Co. Maintains Buy Rating on Stoke Therapeu - GuruFocus

May 14, 2025

Stoke Therapeutics (STOK) Sees Adjusted Price Target Amid Upcomi - GuruFocus

May 14, 2025

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - BioSpace

May 14, 2025

Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up After Better-Than-Expected Earnings - Defense World

May 14, 2025

Stoke Therapeutics Advances with Strong Q1 2025 Results - TipRanks

May 14, 2025

May 13, 2025

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | STOK Stock News - GuruFocus

May 13, 2025

Stoke Therapeutics (STOK) Reports Significant Q1 Revenue Growth - GuruFocus

May 13, 2025